303 related articles for article (PubMed ID: 26980598)
1. Neoantigen Load, Antigen Presentation Machinery, and Immune Signatures Determine Prognosis in Clear Cell Renal Cell Carcinoma.
Matsushita H; Sato Y; Karasaki T; Nakagawa T; Kume H; Ogawa S; Homma Y; Kakimi K
Cancer Immunol Res; 2016 May; 4(5):463-71. PubMed ID: 26980598
[TBL] [Abstract][Full Text] [Related]
2. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.
Şenbabaoğlu Y; Gejman RS; Winer AG; Liu M; Van Allen EM; de Velasco G; Miao D; Ostrovnaya I; Drill E; Luna A; Weinhold N; Lee W; Manley BJ; Khalil DN; Kaffenberger SD; Chen Y; Danilova L; Voss MH; Coleman JA; Russo P; Reuter VE; Chan TA; Cheng EH; Scheinberg DA; Li MO; Choueiri TK; Hsieh JJ; Sander C; Hakimi AA
Genome Biol; 2016 Nov; 17(1):231. PubMed ID: 27855702
[TBL] [Abstract][Full Text] [Related]
3. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.
Braun DA; Hou Y; Bakouny Z; Ficial M; Sant' Angelo M; Forman J; Ross-Macdonald P; Berger AC; Jegede OA; Elagina L; Steinharter J; Sun M; Wind-Rotolo M; Pignon JC; Cherniack AD; Lichtenstein L; Neuberg D; Catalano P; Freeman GJ; Sharpe AH; McDermott DF; Van Allen EM; Signoretti S; Wu CJ; Shukla SA; Choueiri TK
Nat Med; 2020 Jun; 26(6):909-918. PubMed ID: 32472114
[TBL] [Abstract][Full Text] [Related]
4. CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma.
Zhou Q; Qi Y; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Xu L; Dai B; Guo J; Zhu Y; Zhang W; Xu J
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32371459
[TBL] [Abstract][Full Text] [Related]
5. Altered pattern of major histocompatibility complex expression in renal carcinoma: tumor-specific expression of the nonclassical human leukocyte antigen-G molecule is restricted to clear cell carcinoma while up-regulation of other major histocompatibility complex antigens is primarily distributed in all subtypes of renal carcinoma.
Ibrahim EC; Allory Y; Commo F; Gattegno B; Callard P; Paul P
Am J Pathol; 2003 Feb; 162(2):501-8. PubMed ID: 12547708
[TBL] [Abstract][Full Text] [Related]
6. Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy.
Reustle A; Di Marco M; Meyerhoff C; Nelde A; Walz JS; Winter S; Kandabarau S; Büttner F; Haag M; Backert L; Kowalewski DJ; Rausch S; Hennenlotter J; Stühler V; Scharpf M; Fend F; Stenzl A; Rammensee HG; Bedke J; Stevanović S; Schwab M; Schaeffeler E
Genome Med; 2020 Mar; 12(1):32. PubMed ID: 32228647
[TBL] [Abstract][Full Text] [Related]
7. Landscape of immune cell infiltration in clear cell renal cell carcinoma to aid immunotherapy.
Bai D; Feng H; Yang J; Yin A; Qian A; Sugiyama H
Cancer Sci; 2021 Jun; 112(6):2126-2139. PubMed ID: 33735492
[TBL] [Abstract][Full Text] [Related]
8. The immune-checkpoint HLA-G/ILT4 is involved in the regulation of VEGF expression in clear cell renal cell carcinoma.
García M; Palma MB; Verine J; Miriuka S; Inda AM; Errecalde AL; Desgrandchamps F; Carosella ED; Tronik-Le Roux D
BMC Cancer; 2020 Jul; 20(1):624. PubMed ID: 32620162
[TBL] [Abstract][Full Text] [Related]
9. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.
Zhou X; Jun DY; Thomas AM; Huang X; Huang LQ; Mautner J; Mo W; Robbins PF; Pardoll DM; Jaffee EM
Cancer Res; 2005 Feb; 65(3):1079-88. PubMed ID: 15705910
[TBL] [Abstract][Full Text] [Related]
10. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma.
Bukur J; Rebmann V; Grosse-Wilde H; Luboldt H; Ruebben H; Drexler I; Sutter G; Huber C; Seliger B
Cancer Res; 2003 Jul; 63(14):4107-11. PubMed ID: 12874014
[TBL] [Abstract][Full Text] [Related]
11. Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations.
Hansen UK; Ramskov S; Bjerregaard AM; Borch A; Andersen R; Draghi A; Donia M; Bentzen AK; Marquard AM; Szallasi Z; Eklund AC; Svane IM; Hadrup SR
Front Immunol; 2020; 11():373. PubMed ID: 32226429
[TBL] [Abstract][Full Text] [Related]
12. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
13. Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma.
Matsushita H; Hasegawa K; Oda K; Yamamoto S; Asada K; Karasaki T; Yabuno A; Nishijima A; Nejo T; Kobayashi Y; Sato S; Ikeda Y; Miyai M; Takahashi Y; Yamaguchi R; Fujiwara K; Aburatani H; Kakimi K
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461346
[TBL] [Abstract][Full Text] [Related]
14. Data Mining of Prognostic Microenvironment-Related Genes in Clear Cell Renal Cell Carcinoma: A Study with TCGA Database.
Chen B; Chen W; Jin J; Wang X; Cao Y; He Y
Dis Markers; 2019; 2019():8901649. PubMed ID: 31781309
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of human leukocyte antigen class I (HLA-I) is associated with poor prognosis in patients with clear cell renal cell carcinoma.
Yuan J; Liu S; Yu Q; Lin Y; Bi Y; Wang Y; An R
Acta Histochem; 2013 Jun; 115(5):470-4. PubMed ID: 23245688
[TBL] [Abstract][Full Text] [Related]
16. Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups.
de Velasco G; Miao D; Voss MH; Hakimi AA; Hsieh JJ; Tannir NM; Tamboli P; Appleman LJ; Rathmell WK; Van Allen EM; Choueiri TK
Cancer Immunol Res; 2016 Oct; 4(10):820-822. PubMed ID: 27538576
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma.
Ghatalia P; Gordetsky J; Kuo F; Dulaimi E; Cai KQ; Devarajan K; Bae S; Naik G; Chan TA; Uzzo R; Hakimi AA; Sonpavde G; Plimack E
J Immunother Cancer; 2019 May; 7(1):139. PubMed ID: 31138299
[TBL] [Abstract][Full Text] [Related]
18. Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.
Mulders P; Tso CL; Gitlitz B; Kaboo R; Hinkel A; Frand S; Kiertscher S; Roth MD; deKernion J; Figlin R; Belldegrun A
Clin Cancer Res; 1999 Feb; 5(2):445-54. PubMed ID: 10037196
[TBL] [Abstract][Full Text] [Related]
19. Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status.
Roemer MG; Advani RH; Redd RA; Pinkus GS; Natkunam Y; Ligon AH; Connelly CF; Pak CJ; Carey CD; Daadi SE; Chapuy B; de Jong D; Hoppe RT; Neuberg DS; Shipp MA; Rodig SJ
Cancer Immunol Res; 2016 Nov; 4(11):910-916. PubMed ID: 27737878
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma.
Ibrahim EC; Guerra N; Lacombe MJ; Angevin E; Chouaib S; Carosella ED; Caignard A; Paul P
Cancer Res; 2001 Sep; 61(18):6838-45. PubMed ID: 11559559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]